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ABSTRACT 
Objective: To perform the translation, cross-cultural adaptation and validation of the Quantitative Myasthenia Gravis Score (QMGS) 
to Brazilian Portuguese in accordance with international ethical standards. Methods: The following steps were taken: (1) implementation of 
the translation protocol and transcultural adaptation, (2) validation of the adapted content, and (3) assessment of reliability. To check intra- 
and inter-observer reproducibility, each patient underwent two interviews with interviewer-A and one with B. The QMGS was compared 
to the Myasthenia Gravis Composite Scale and Myasthenia-specific Quality of Life Questionnaire. Results: Our study group consisted of 
30 patients, with a mean age of 47.6±11.4 years and a mean duration of illness of 11.33±8.49 years. Correlation between the QMGS and MGC 
was very strong (r = 0.928; p < 0.001) and substantial between the QMGS and MG-QOL 15 (r = 0.737; p < 0.001). Conclusion: The Brazilian 
Portuguese translation, and validation of the QMGS was successfully performed. 
Keywords: myasthenia gravis; cross-cultural comparison; translations; validation studies.
RESUMO 
Objetivo: O objetivo foi realizar a tradução e validação do teste quantitativo para Miastenia Gravis (QMGS) para Português do Brasil, de acordo 
com as diretrizes internacionais. Métodos: Foram realizadas as etapas de implementação do protocolo de tradução e adaptação transcultural, 
validação do conteúdo adaptado e avaliação da confiabilidade. Para verificar a reprodutibilidade intra e inter-observador cada paciente foi 
submetido a duas entrevistas por um entrevistador-A e um B. O QMGS foi comparado ao MG Composite Scale e Myasthenia-specific Quality 
of Life Questionnaire. Resultados: O estudo inclui 30 pacientes, com a média de idade de 47,6±11,4 anos e tempo médio de doença de 
11,33±8,49 anos. A correlação entre QMGS e MGC apresentou-se muito forte (r = 0,928; p < 0,001) e substancial entre QMGS e MG-QOL 15 
(r = 0,737; p < 0,001). Conclusão: A tradução, e validação do QMGS para o português do Brasil foi realizada com sucesso. 
Palavras-chave: miastenia gravis; comparação transcultural; traduções; estudos de validação.
Myasthenia gravis (MG) is a chronic autoimmune neu-
romuscular disorder characterized by weakness of the skel-
etal muscles1. In approximately 85% to 90% of patients with 
MG, antibodies against nicotinic acetylcholine receptors are 
identified in the neuromuscular junctions, with a smaller group 
of patients having autoantibodies against muscle-specific 
kinase2, low-density lipoprotein-related protein 4, and even 
against agrin3,4. 
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The incidence and prevalence rates of MG vary greatly 
from country to country, making it difficult to generalize the 
data. Nonetheless, crude estimates are possible using the 
combination of pooled estimates and the range of observed 
frequencies. The incidence of all MG is: 5.3 per million per-
son-years (C.I.: 4.41, 6.12), range: 1.7 - 21.3, and prevalence: 
77.67 cases per million (C.I.: 63.98, 94.30), range: 15 - 1795.
The Myasthenia Gravis Foundation of America rec-
ommends that the Quantitative Myasthenia Gravis Score 
(QMGS) be used in all prospective clinical trials on MG6,7. 
The QMGS was developed by Besinger et al. in 1983 as 
a clinical scoring system to assess clinical outcomes in 
patients with MG8. The original scale comprised eight items, 
graded from 0 to 3, where 3 is indicative of a higher sever-
ity of impairment. In 1987, Tindall et al. modified the scale, 
increasing the number of items from eight to 13 to improve 
the responsiveness of the scale in evaluating outcomes of 
treatment interventions for MG9,10. 
In 1992, Tindall et al.10 used the modified QMGS to eval-
uate the effectiveness of a six-month treatment with cyclo-
sporine (5 mg/kg per body weight) compared to a placebo 
group. Thirty-nine patients were randomized to the cyclo-
sporine or the placebo group, with outcome measures eval-
uated monthly. Outcome measures included: the QMGS, 
anti-human acetylcholine receptor antibody titer, and dose 
of corticosteroid medication. At the six-month end-point, 
patients in the cyclosporine group exhibited significant 
increases in strength (p = 0.004) and reduction in antirecep-
tor antibody titer (p = 0.01), compared to those in the pla-
cebo group. Subsequently, the QMGS scale underwent fur-
ther modification by Barohn et al.11
In its current format, the QMGS is a 13-item measurement 
tool used to quantify disease severity in patients with MG, 
including ocular, bulbar, respiratory, and limb function, with a 
total score range of 0 to 39, where a higher score is indicative of 
greater disease severity. The reliability and longitudinal valid-
ity of the QMGS have been demonstrated in several studies12,13.
From a clinical perspective, the QMGS provides an easy-
to-use outcome measure that requires minimal equipment. 
Moreover, a change of 3.5 points in the total score is consid-
ered a clinically meaningful improvement for patients with 
MG. Therefore, the aim of this study was to perform the trans-
lation, cultural adaptation, and validation of the QMGS to 
extend its application in clinical practice and research with 
patients with MG in the Portuguese community of Brazil. 
According to our knowledge, this is the first translation and 
cultural adaptation of QMGS for another language.
METHODS
A search of the literature was performed to identify 
previous research on the adaptation and use of the QMGS 
for the Brazilian Portuguese population. The following 
databases were searched using the combination keywords 
“Quantitative Myasthenia Gravis Score and Portuguese 
validation”: Medline, PubMed, Scientific Electronic 
Library Online, and Scientific and Technical Literature of 
Latin America and the Caribbean. No published informa-
tion was identified. 
Four neuromuscular disease research centers collabo-
rated in our study. All methods and procedures were per-
formed in accordance with the ethical standards established 
in the 1964 Declaration of Helsinki (as revised in Hong Kong 
in 1989 and Edinburgh, Scotland in 2000). Our study com-
plied with the Regulatory Guidelines and Norms for Research 
Involving Human Subjects of the National Health Board 
of the Brazilian Health Ministry, issued in December 2012. 
Our study is part of a previously-published research proto-
col14, approved by the Human Research Ethics Committee of 
Nove de Julho University (Brazil) under process no. 360.488 
and registered with the World Health Organization under 
Universal Trial Number (UTN) U1111-1147-7853 and the 
Brazilian Registry of Clinical Trials (REBEC) RBR -7ckpdd. 
Written informed consent was obtained prior to enroll-
ment and participants were allowed to withdraw from the 
study, at any time, without consequence. Our eligibility cri-
teria were as follows: a clinical diagnosis of MG according 
to the Myasthenia Gravis Foundation of America (MGFA) 
criteria; 18 to 75 years of age; both sexes; clinically stable 
patients; and capable of and willing to provide informed 
consent. Excluded from our study were patients with other 
neuromuscular, cardiovascular, and respiratory diseases, 
episodes of clinical decompensation of their disease in the 
two months prior to the study, a prior stroke, history of men-
tal disease, or abuse of drugs and/or alcohol. We undertook 
the process of translation, cultural adaptation, and valida-
tion of the QMGS based on previously-published standard-
ized rules15,16. A flowchart of the study is shown in Figure 1.
First stage
The original version of the QMGS was translated from 
English to Brazilian Portuguese by three bilingual transla-
tors, a physical therapist; a neurologist, and a certified pro-
fessional translator, all of whom were blinded to the purpose 
of our study. The three translated versions were evaluated, 
compared, and merged into an initial Brazilian Portuguese 
draft version.
Second stage
Two native English-speaking translators, a certified pro-
fessional translator, and a neurologist with no knowledge 
of the QMGS or of our research aim independently per-
formed a back-translation of the final draft version from 
Brazilian-Portuguese to English. The back-translated English 
version was compared to the original English version with 
adjustments made to the Brazilian-Portuguese version to 
correct identified discrepancies.
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Third stage
A cultural adaptation of the Brazilian-Portuguese ver-
sion of the QMGS, updated after the back-translation pro-
cess, was subsequently undertaken, enrolling 10 patients 
with MG from the four neuromuscular disease research 
centers collaborating in our study. We added the phrase 
“difficult to understand” as a response option in the 
Brazilian-Portuguese version. Initially, we established an 
understanding of each item by 90% of healthcare pro-
fessionals for the Brazilian-Portuguese translation to be 
acceptable, with the translation process to be repeated if 
this threshold was not achieved. 
Five neurologists and five physiotherapists were recruited 
to verify the clarity of clinical terminology for the translated 
QMGS version. Again, a threshold of ≥90% was used for the 
translation to be deemed acceptable for clinical practice. 
In completing their review, the healthcare professionals also 
commented on the overall clarity of the QMGS. Ambiguous 
terms were discussed and replaced by alternative terms hav-
ing semantic equivalence and appropriate to the Brazilian 
culture. A final version of the Brazilian Portuguese QMGS was 
consolidated without compromising the intended meaning 
of the original version (Figure 2). 
Comprometimento Nenhum Leve Moderado Grave
Pontos
Graduação 0 1 2 3
Visão dupla (olhar fixo lateral) (segundos) 60 11-59 1-10 Espontâneo
Ptose (olhar fixo para cima) (segundos) 60 11-59 1-10 Espontâneo
Músculos faciais
Fechamento 
normal das 
pálpebras.
Fechamento 
completo. 
Resistência 
fraca.
Fechamento 
completo.
Sem resistência
Fechamento 
incompleto.
Deglutição (120 ml água) Normal Tosse mínima ouLimpar a garganta
Tosse intensa, 
engasga ou 
regurgitação nasal
Não consegue 
engolir Teste não 
realizado.
Contar em voz alta de 1 a 50. (início da disartria) Nenhum sinalaté 50
Disartria 
entre 30-49
Disartria 
entre 10-29
Disartria 
até 9
Braço direito estendido (90º sentado) (segundos) 240 90-239 10-89 0-9
Braço esquerdo estendido (90º sentado) (segundos) 240 90-239 10-89 0-9
Capacidade Vital Forçada (% do predito) ≥ 80% 65-79% 50-64% <50%
Preensão palmar direita (kg)
Homem ≥45 15-44 5-14 0-4
Mulher ≥30 10-29 5-9 0-4
Preensão palmar esquerda (kg)
Homem ≥ 35 15-34 5-14 0-4
Mulher ≥25 10-24 5-9 0-4
Em supino, manter a cabeça erguida em 45 graus. 
(segundos) 120 30-119 1-29 0
Perna direita estendida 45 a 50º (supino) 
(segundos) 100 31-99 1-30 0
Perna esquerda estendida 45 a 50º (supino) 
(segundos) 100 31-99 1-30 0
Figure 2. Quantitative tests for myasthenia gravis in Brazilian Portuguese.
FIRST STAGE
First translation of the QMGS original version
3 bilingual translators
(physiotherapist, physician, sworn translator) 
Back translation
2 English translators
(phsysician, sworn translator)
SECOND STAGE
Cross-cultural adaptation
(5 neurologist physicians, 5 physiotherapists 
and 10 myasthenia gravis patients
THIRD STAGE
Validation
Reproducibility and validity of the QMGS 
Brazilian Portuguese version
Two trained and independent neurologists 
and 30 MG patients
Figure 1. Flowchart of the study.
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Reliability and validity of the QMGS Brazilian 
Portuguese version
A sample of convenience of 30 patients, with a confirmed 
clinical diagnosis of MG based on the criteria of the MGFA 
and confirmed by the neurologists, was recruited to evaluate 
the reliability and validity of the Brazilian-Portuguese version 
of the QMGS. The 10 patients who participated in Phase III, 
cultural adaptation, were included in the validation compo-
nent of our study. 
Two trained neurologists (observer A and B) evaluated 
the QMGS at three time points. To assess inter-observer reli-
ability, neurologists completed the QMGS, independently, 
within a two-hour interval. To assess intra-observer reliabil-
ity, observer A completed the QMGS evaluation at one-week 
intervals, with interviews conducted at the same time of day. 
The concurrent validity of the Brazilian Portuguese ver-
sion of the QMGS was evaluated against the Portuguese ver-
sion of the Myasthenia Gravis Composite Scale (MGC)17 and 
the Portuguese version of the 15-item Myasthenia-specific 
Quality of Life Questionnaire (MG-QOL 15)18 in a group of 
30 patients with MG. The same evaluator applied the MGC 
and QMGS. The MGC is a 10-item scale designed to eval-
uate the function of patients with MG, with the response 
scale for each MGC items weighted in terms of the impact 
of the item on overall function. For example, ptosis scores 
3 points, hip flexion weakness scores 5 points, and severity 
of respiratory symptoms for ventilator-dependent patients 
scores 9 points. The maximum possible score on the MGC 
is 50 points, with a higher score reflecting a more severe 
disease state. The validity and reliability of the MGC has 
been established, both in the United States and Europe, 
with a 3-point reduction in total score being indicative of 
a clinically meaningful improvement in the function of a 
patient with MG19,20. 
The 15-item MG-QOL is an easy-to-use instrument that 
evaluates three dimensions of health-related quality of life. 
The 15 items are scored on a scale of 0 to 4, with the score 
on each item summed to provide the total score. A clinically 
meaningful cutoff is not available for the MG-QOL. Therefore, 
the total score is interpreted along a continuum, with a 
higher score being indicative of a perception of an increas-
ingly poorer quality of life. Both the MGC and MG-QOL are 
widely used to evaluate the physical, social, and psychologi-
cal aspects of life of patients with MG and are used to derive 
an overall evaluation of the health-related quality of life in 
this clinical population18,21.
Lung function tests were performed on the day follow-
ing the clinical evaluation, using the KoKo® Sx 1000 sys-
tem (nSpire Health Inc., Longmont, CO, USA), based on the 
guidelines of the Brazilian Society of Pneumology22. Peak 
forced expiratory volume (measured over a 1-s expiration) 
and forced vital capacity were used for analysis, regardless of 
the form of the curve (i.e., peak values were not necessarily 
obtained from the best expiratory curves). 
Handgrip strength was assessed using the JAMAR hydrau-
lic hand dynamometer device (Lafayette Instrument Company, 
Inc., Lafayette, IN, USA), which is widely used to provide a sim-
ple measure of hand strength in clinical populations with neu-
romuscular diseases. The JAMAR hand dynamometer is adjust-
able to the size of a patient’s hand23. Handgrip strength was 
evaluated with patients in a sitting position, with the shoulder 
in 180º of forward flexion and the elbow in full extension.
Statistical analysis
Prior to data analysis, normality of data distribution was 
evaluated using the Shapiro-Wilk test. For parametric data, 
including anthropometric and demographic measures, the 
mean and standard deviation values were calculated. 
Intra- and inter-observer reliability was assessed using 
Pearson’s correlation coefficient and the intra-class corre-
lation coefficient with two-way mixed effects model where 
people effects are random and measures effects are fixed. The 
intra- and inter-observer reliability was also evaluated for 
each item of the QMGS using Cohen’s kappa test, with the fol-
lowing interpretation of the kappa index: < 0, no agreement; 
0–0.20, slight agreement; 0.21–0.40, fair agreement; 0.41–0.60, 
moderate agreement; 0.61–0.80, substantial agreement; and 
0.81–1, excellent agreement. 
Spearman’s rank correlation coefficient was used to 
evaluate agreement between the score on the items of the 
QMGS and the MGC and MG-QOL. For all analyses, a p value 
< 0.01 was considered significant. Statistical analysis was 
performed with StatView 5.0 (SAS Institute, Cary, N.C., USA), 
and SPSS software (version 23.0, SPSS Inc. Chicago, IL, USA).
RESULTS
Demographic data
Thirty-six patients (25 women), with a confirmed diag-
nosis of MG using the criteria of the MGFA, were identi-
fied from the four neuromuscular clinics involved in our 
study: the Neuromuscular Diseases Research department 
of the Universidade Federal de São Paulo; the Department of 
Neurology of the Faculty of Sciences, physicians from Santa 
Casa de São Paulo; the Department of Neurology of the Hospital 
do Servidor Público Estadual; and the Child  Neurology Clinic of 
the Hospital das Clínicas, Faculdade de Medicina, Universidade 
de São Paulo. Six patients did not meet our eligibility criteria 
and, therefore, were not enrolled in our study. 
The demographic, clinical data, and classification of dis-
ease severity for our final study groups are shown in Table 1. 
Of the 30 patients forming our study group, 24 were women, 
with a mean age of 47.6 ± 11.4 years (range, 32–74 years), and a 
mean duration of illness of 11.33 ± 8.49 years. The distribution 
of MGFA classification was as follows: four patients, Class I; 
17 patients, Class II; eight patients, Class III; no patients in 
Class IV or V. Among the patients in our study group, 96% 
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were using cholinesterase inhibitors and 36% were using 
immunosuppressant drugs. 
On average, the QMGS was completed in 32 minutes, with 
an additional 18 minutes required for assessment of forced 
vital capacity by spirometry and eight minutes for hand 
grip strength. The kappa index of inter- and intra-observer 
reliability for each item of the QMGS is reported in Table 2, 
with all kappa values ≥0.81, indicative of an excellent reli-
ability for all items. Overall inter- and intra-observer reliabil-
ity was confirmed by the intra-class correlation coefficient 
Table 1. Baseline clinical and demographic variables. 
Variables Patients (n = 30) (%)
Female/Male 24/6 - 
Age (years) 47.6 ± 11.4  -
Body Mass Index 27.5 ± 5.4  -
MGFA
I 2 6.6
IIA 17 56.6
IIB 2 6.6
IIIA 5 16.6
IIIB 4 13.3
QMGS 11.4 ± 5.7  -
MGC 12.93 ± 7  -
MG QOL – 15 score 21.6 ± 12  -
Note: Values shown are number (%), or mean ± SD. MGFA: Myasthenia 
Gravis Foundation of America Clinical classification. QMGS: Quantitative 
Myasthenia Gravis Score; MGC: Myasthenia Gravis Composite Scale; MG-
QOL: Questionnaire of Life Quality Specific for Myasthenia Gravis – 15 items.
Table 2. Assessment of intra- and inter-interviewer 
reproducibility of Quantitative Myasthenia Gravis score 
(QMGS) with Cohen’s kappa.
QMGS items Intra-interviewer Inter-interviewer
Double vision 0.896 0.897
Ptosis 0.890 0.721
Facial muscles 0.947 0.893
Swallowing 0.710 0.815
Speech following counting 
aloud from 1–50 1.000 0.930
Right arm outstretched 0.862 0.761
Left arm outstretched 0.841 0.792
Forced vital capacity 1.000 0.762
Right hand grip 1.000 0.826
Left hand grip 0.939 0.876
Head lifted 0.772 0.854
Right leg outstretched 0.875 0.875
Left leg outstretched 0.890 0.890
Table 3. Analysis of the reproducibility by means of the Pearson’s correlation coefficient and of the intra-class correlation 
coefficient values for the total score.
Coefficient Intra-interviewer Inter-interviewer mean ± SD QMGS-A mean ± SD QMGS-B mean ± SD QMGS-A2
Pearson’s 0.998* 0.991*
11.43 ± 5.7 11.50 ± 5.2 11.37 ± 5.6
Intra-class 0.999** 0.994***
*p < 0.001; **CI = 95% (0.998–1.000); ***CI: 95% (0.987–0.997). SD: Standard Deviation; QMGS-A: Quantitative Myasthenia Gravis score interviewer A; QMGS-B: 
Quantitative Myasthenia Gravis interviewer B; Quantitative Myasthenia Gravis score interviewer A2 (second interview).  
and Pearson’s correlation coefficient reported in Table 3. 
Correlation between the QMGS and MGC was very strong 
(R = 0.928; p < 0.001) and substantial between the QMGS and 
MG-QOL15 (R = 0.737; p < 0.001) as shown in Figure 3.
DISCUSSION
The use of common assessment tools is advocated by 
the Task Force of the Medical Scientific Advisory Council, 
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Figure 3. Correlation between the QMGS and MGC and between 
the QMGS and MG-QOL15.
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with the MGFA proposing a series of classification systems 
and definitions of response to therapy for MG patients7, 
to achieve greater uniformity in the recording and report-
ing of clinical trials for MG. The QMGS is among the recom-
mended assessment tools. However, to be applicable to dif-
ferent ethnic groups, patient-report assessments, such as the 
QMGS, require translation and validation for each popula-
tion. A rigorous process of translation and cultural adapta-
tion is required to ensure congruity with the original version 
of the measurement tool, facilitate uptake of the translated 
version, and eliminate the risk of systematic bias of results. 
For these reasons, we performed the translation and cul-
tural adaption of the original English version of the QMGS for 
use with patients with MG of Portuguese ethnicity in Brazil 
according to published international standards15,16. 
The excellent intra- and inter-observer reliability and 
clinically acceptable concurrent validity of the QMGS that 
we report in our study are comparable to values previously 
reported. Sharshar et al.12 evaluated the inter-observer reli-
ability and concurrent validity of the QMGS against the 
Myasthenia Muscle Score. Among a group of 22 patients 
with MG, including 13 men and nine women, with a mean 
age of 63 years (range, 25 to 80 years), they reported high 
inter-observer agreement and a high correlation in score 
between the QMGS and Myasthenia Muscle Score. Therefore, 
we propose that our translated version of the QMGS has the 
reliability required for its use in clinical trials and in practice. 
The longitudinal construct validity of the QMGS was con-
firmed by Bedlack et al. in a prospective study with 53 patients 
with MG13. In this study, the authors demonstrated the corre-
lation between the QMGS and manual muscle testing, as well 
as providing evidence of the responsiveness of the QMGS to 
differentiate change in disease severity between two visits as: 
unchanged, improved, or worse. 
In our study, we found a very strong correlation between 
the QMGS and the MGC, as well as between the QMGS and 
the 15-item MG-QOL. Our results are comparable to those 
reported by Barnett et al.24 who observed a good association 
between the 15-item MG-QOL and the QMGS. We also con-
firmed the concordance between the QMGS and the MGFA 
classification of disease severity, Class I to III. It is impor-
tant to acknowledge that our study group did not include 
patients in the MGFA Class IV and V. Barnett et al.25 similarly 
confirmed the sensitivity of the QMGS to differentiate dis-
ease severity among patients with MG, as well as to quantify 
treatment effectiveness. In particular, Barnett et al. provided 
evidence of the discriminative value of the timed items of 
the QMGS, evaluating upper and lower limb function and 
neck endurance. 
In the process of validating the Brazilian Portuguese version 
of the QMGS, patients in our study group reported excellent 
understanding and applicability of the QMGS, with health pro-
fessionals confirming the clinical applicability of the translated 
QMGS. Moreover, reliability measures (inter- and intra-observer 
reliability) for the translated QMGS were excellent, meeting the 
international standards for the clinical and research use of a 
translated and culturally-adapted measurement tool. 
In conclusion, based on our results, we can affirm that 
the Brazilian Portuguese translation, cultural adaptation, 
and validation of the QMGS was successfully performed. 
We believe that the use of our Brazilian Portuguese version 
of the QMGS will improve care of patients with MG, includ-
ing more precise monitoring of the clinical rehabilitation pro-
cess, as well as a more effective comparison of clinical status.
463Oliveira EF et al. Quantitative Myasthenia Gravis Score
12. Sharshar T, Chevret S, Mazighi M, Chillet P, Huberfeld G, 
Berreotta C et al. Validity and reliability of two muscle 
strength scores commonly used as endpoints in assessing 
treatment of myasthenia gravis. J Neurol. 2000;247(4):286-90. 
https://doi.org/10.1007/s004150050585
13. Bedlack RS, Simel DL, Bosworth H, Samsa G, 
Tucker-Lipscomb B, Sanders DB. Quantitative myasthenia 
gravis score: assessment of responsiveness and 
longitudinal validity. Neurology. 2005;64(11):1968-70. 
https://doi.org/10.1212/01.WNL.0000163988.28892.79
14. Oliveira EF, Urbano JJ, Santos IR, et al. Brazilian 
translation, crosscultural adaptation and validation of 
the MG composite scale and quantitative myasthenia 
gravis testing form: a multicentric study protocol. 
Man Ther Posturology Rehabil J. 2016;14:1-5. 
https://doi.org/10.17784/mtprehabjournal.2016.14.342
15. Guillemin F, Bombardier C, Beaton D. Cross-cultural adaptation 
of health-related quality of life measures: literature review and 
proposed guidelines. J Clin Epidemiol.1993;46 (12):1417-32. 
https://doi.org/10.1016/0895-4356(93)90142-N
16. Guillemin F. Cross-cultural adaptation and validation of 
health status measures. Scand J Rheumatol. 1995;24(2):61-3. 
https://doi.org/10.3109/03009749509099285
17. Oliveira EF, Lima VC, Perez EA, Polaro MN, Valério BC, 
Pereiro JR et al. Brazilian-Portuguese translation, cross-cultural 
adaptation and validation of myasthenia gravis composite scale: 
a multicentric study. Arq Neuropsiquiatr. 2016;74(11):914-20. 
https://doi.org/10.1590/0004-282x20160129
18. Mourão AM, Araújo CM, Barbosa LSM, Gomez RS, Burns TM, 
Lemos SMA et al. Brazilian cross-cultural translation and 
adaptation of the’Questionnaire of Life Quality Specific 
for Myasthenia Gravis - 15 items’. Arq Neuropsiquiatr. 
2013;71(12):955-8. https://doi.org/10.1590/0004-282X20130180
19. Sadjadi R, Conaway M, Cutter G, Sanders DB, Burns TM. Psychometric 
evaluation of the myasthenia gravis composite using Rasch analysis. 
Muscle Nerve. 2012;45(6):820-5. https://doi.org/10.1002/mus.23260
20. Burns TM, Conaway MR, Cutter GR, Sanders DB. Construction 
of an efficient evaluative instrument for Myasthenia gravis: 
the MG composite. Muscle Nerve. 2008;38(6):1553-62. 
https://doi.org/10.1002/mus.21185
21. Burns TM, Grouse CK, Conaway MR, Sanders DB. Construct and 
concurrent validation of the MG-QOL15 in the practice setting. Muscle 
Nerve. 2010;41(2):219-26. https://doi.org/10.1002/mus.21609 
22. Pereira CAC. Diretrizes para testes de função pulmonar. J Pneumol. 
2002;28(supl 3):S1-82. 
23. Figueiredo IM, Sampaio RF, Mancini MC, Silva FCM, Souza MAP. 
Test of grip strength using the Jamar dynamometer. Acta Fisiatr. 
2007;14(2):104-10. https://doi.org/10.5935/0104-7795.20070002
24. Barnett C, Katzberg H, Nabavi M, Bril V. The quantitative myasthenia 
gravis score: comparison with clinical, electrophysiological, and 
laboratory markers. J Clin Neuromuscul Dis. 2012;13(4):201-5. 
https://doi.org/10.1097/CND.0b013e31824619d5
25. Barnett TC, Bril V, Davis AM. Performance of individual items of 
the quantitative myasthenia gravis score. Neuromuscul Disord. 
2013;23(5):413-7. https://doi.org/10.1016/j.nmd.2013.02.008
